Cytosorbents (CTSO) Projected to Post Quarterly Earnings on Wednesday

Cytosorbents (NASDAQ:CTSO) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $9.78 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Cytosorbents Price Performance

NASDAQ:CTSO opened at $0.80 on Wednesday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11. The company has a 50-day moving average of $0.68 and a 200-day moving average of $0.78. Cytosorbents has a 52 week low of $0.60 and a 52 week high of $1.39. The company has a market capitalization of $50.24 million, a price-to-earnings ratio of -4.44 and a beta of 1.36.

Institutional Trading of Cytosorbents

Several hedge funds have recently added to or reduced their stakes in CTSO. Avenir Corp grew its stake in Cytosorbents by 2.9% in the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after acquiring an additional 147,261 shares during the period. Vanguard Group Inc. raised its position in shares of Cytosorbents by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares during the period. CIBC Bancorp USA Inc. bought a new position in shares of Cytosorbents during the 3rd quarter valued at about $161,000. Citadel Advisors LLC grew its position in shares of Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after purchasing an additional 37,519 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Analyst Ratings Changes

CTSO has been the topic of several research reports. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, January 9th. Finally, HC Wainwright dropped their price target on shares of Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a research note on Friday, November 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cytosorbents has a consensus rating of “Hold” and a consensus target price of $5.38.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.